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Abstract
Background—For adults, the Advisory Committee on Immunization Practices (ACIP) 
recommends a single dose of tetanus, diphtheria and acellular pertussis vaccine (Tdap) followed 
by tetanus and diphtheria toxoids (Td) booster doses every 10 years thereafter.
Purpose—To assess recent Td and Tdap vaccination among adult populations.
Methods—The 2013 BRFSS data were analyzed in 2015 to assess Td and Tdap vaccination 
coverage among adults at national and state levels. Multivariable logistic regression and predictive 
marginal models were performed to identify factors independently associated with vaccination.
Results—Overall, national vaccination coverage among adults ≥18 years for Td was 57.5% and 
for Tdap was 28.9%. Among states, Td vaccination coverage ranged from 47.8% in Nevada to 
73.1% in Minnesota, and Tdap coverage ranged from 17.7% in Mississippi to 47.6% in 
Minnesota. Characteristics independently associated with an increased likelihood of Tdap 
vaccination among adults ≥18 years were: younger age; being female; American Indian/Alaska 
Native (AIAN) race; being never married; higher education; not being in the workforce, reporting 
a household income ≥$75,000; living in the West or Midwest of the United States; reporting 
excellent, very good, good, or fair health; having health insurance; having a healthcare provider; 
having a routine checkup in the previous year; receipt of influenza vaccination in the previous 
year; and having ever received pneumococcal vaccination.
Conclusions—By 2013, Td and Tdap vaccination coverage were 57.5% and 28.9%, 
respectively. Coverage varied by state. Implementation of evidence-based programs are needed to 
improve Td and Tdap vaccination levels among adult populations.
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Introduction
Pertussis, a respiratory illness commonly known as whooping cough, is a very contagious 
disease caused by the bacteria Bordetella pertussis. Pertussis remains endemic in the United 
States despite longstanding routine childhood pertussis vaccination. Since the 1980s, the 
number of reported pertussis cases has steadily increased, especially among adolescents and 
adults (1–5). Overall, reported cases of pertussis during 2013 were 28,639.1–3 An average of 
22,785 pertussis cases were reported annually from 2004 to 2013.1–3
Vaccination offers the best protection against pertussis infection. Adults and adolescents 
may become susceptible to pertussis due to waning immunity from childhood vaccinations. 
To protect adolescents and adults against pertussis, the Advisory Committee on 
Immunization Practices (ACIP) recommended the tetanus, diphtheria, and acellular pertussis 
vaccine (Tdap) in 2005 as a one-time replacement for the decennial tetanus diphtheria (Td) 
booster dose among persons 11–64 years.4–5 In October 2010, ACIP recommended Tdap for 
adults ≥65 years who have or who anticipate having close contact with an infant <1 year 
regardless of the interval since the last tetanus or diphtheria-toxoid containing vaccine.6 In 
February 2012, ACIP expanded the general adult Tdap recommendation to include all adults 
≥65 years.7
This study used data from the 2013 Behavioral Risk Factor Surveillance System (BRFSS) to 
assess national and state-specific Td and Tdap vaccination coverage and identify factors 
independently associated with vaccination among adult populations in the United States. 
Such information will help in identifying strategies to improve vaccination coverage among 
adult populations.
Methods
The 2013 BRFSS data were analyzed in 2015. The BRFSS is a continuous, population-based 
telephone survey coordinated by state health departments in collaboration with the Centers 
for Disease Control and Prevention (CDC). The BRFSS collects information from non-
institutionalized adults ≥18 years. The BRFSS is conducted monthly in all 50 states and the 
District of Columbia (D.C.). The objective of the BRFSS is to collect uniform, state-specific 
data on self-reported preventive health practices and risk behaviors that are linked to chronic 
diseases, injuries, and preventable infectious diseases. Individuals are selected randomly 
using a multistage cluster design. Data are weighted by age, sex, and, in some states, race/
ethnicity, to reflect each area’s estimated adult population.8 Beginning in 2011, surveys 
included landline and cellular telephone households and used a new method for weighting.9 
For the 2013 BRFSS, the median state-specific AAPOR (American Association of Public 
Opinion Research) landline, cellular phone, and combined response rates were 49.6% 
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(range: 28.0%–63.7%), 37.8% (range: 19.6%–62.6%), and 46.4% (range: 29.0%–60.3%), 
respectively.10
To determine Td and Tdap vaccination status in all states, a new question regarding Td and 
Tdap vaccination was added to the 2013 BRFSS core questionnaire. Respondents were 
asked “Since 2005, have you had a tetanus shot?” Respondents who answered “yes” were 
asked “Was this Tdap, the tetanus shot that also has pertussis or whooping cough vaccine?” 
Respondents without “yes” or “no” responses for the questions were excluded from the 
assessment of Tdap vaccination. Sensitivity calculations were conducted to assess the 
magnitude of potential bias in this method of calculation, assuming those who answered 
they received a tetanus shot but were not sure what type either received Tdap vaccine or did 
not receive Tdap.
Td and Tdap vaccination levels were stratified by demographic and access to care 
characteristics: age group (18–49, 50–64, 65+), race/ethnicity (non-Hispanic whites, non-
Hispanic black, Hispanic, non-Hispanic Asian, non-Hispanic American Indian/Alaska 
Native (AIAN), other), marital status (married or unmarried couple [unmarried couple 
indicates that someone is living with a partner before marriage], divorced/widowed/
separated, never married), education (less than high school, high school graduate, some 
college or technical school, college graduate or higher), employment status (employed, 
unemployed, not in work force), household income (<$20,000, $20,000–$49,999, $50,000–
$74,999, $75,000 or more), region (Northeast, Midwest, South, West), perceived health 
status (excellent/very good, good, fair, poor), medical insurance status (insured, uninsured), 
having a personal health care provider (yes, no), time since last routine checkup (<1year, ≥1 
year), unable to see doctor due to cost (yes, no), influenza vaccination in the last 12 month 
(yes, no), and ever received pneumococcal vaccination (yes, no).
SUDAAN (Software for the statistical analysis of correlated data, Research Triangle 
Institute, Research Triangle Park, NC) was used to calculate point estimates and 95% 
confidence intervals (CIs). All analyses were weighted to reflect the age, sex, and race/
ethnicity of the U.S. non-institutionalized civilian population (Census-based population was 
used to base the age, sex, and race/ethnicity weights used in the analyses). All tests were 2-
tailed with the significance level set at α<0.05. State-specific Td and Tdap vaccination 
coverage was also evaluated. Predictive marginal models were used to generate adjusted 
prevalence ratios and identify variables independently associated with Td and Tdap 
vaccination among persons ≥18 years.
Results
A total of 479,201 adults ≥18 years from the 2013 BRFSS were included in the study. 
Demographic characteristics of the study population are given in Table 1. The majority of 
participants were 18–49 years (55.0%), female (51.3%), non-Hispanic white (65.0%), 
married or a member of an unmarried couple (56.1%), had at least some college [or 
technical school] education (56.3%), were employed (56.1%), had medical insurance 
(82.5%), and had a personal health care provider (76.2%).
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Td vaccination coverage was 57.5% (95% confidence interval [CI]=57.2%, 57.9%) among 
adults ≥18 years. Td vaccination coverage was significantly higher among adults 18–49 
years (61.3%) and 50–64 years (56.0%) compared with adults ≥65 years (48.9%) (p<0.05) 
(Table 2). Td coverage was significantly lower among non-Hispanic blacks (53.4%), 
Hispanics (52.7%), and non-Hispanic Asians (52.6%) compared with non-Hispanic whites 
(59.3%) (p<0.05), but was higher for AIAN (64.1%) compared with non-Hispanic whites 
(p<0.05). Td vaccination coverage was significantly higher among persons who were male; 
were never married; reported having higher education; reported higher income; lived in the 
Midwest region of the United States; reported excellent, very good, or good health; reported 
having medical insurance; reported having a personal health care provider; reported having a 
routine checkup in the previous year; did not report that cost prevented them from seeing a 
doctor; reported receipt of influenza vaccination in the previous year; and reported having 
ever received pneumococcal vaccination (p<0.05) (Table 2). Td vaccination coverage was 
significantly lower among persons who reported being widowed, divorced, or separated; 
were unemployed or not in work force; or lived in the Southern region of the United States 
(p<0.05) (Table 2).
Overall, Tdap vaccination coverage was 28.9% (CI=28.5%, 29.2%) among adults ≥18 years. 
Tdap vaccination coverage was significantly higher among adults 18–49 years (34.4%) and 
50–64 years (25.4%) compared with adults ≥65 years (18.7%) (p<0.05) (Table 2). Tdap 
coverage was significantly higher among non-Hispanic whites (29.9%) compared with non-
Hispanic blacks (25.3%) and Hispanics (26.0%) (p<0.05), but was higher for AIAN (34.3%) 
compared with non-Hispanic whites (p<0.05). Characteristics associated with Tdap 
vaccination were similar to those for Td, except females had higher Tdap coverage while 
males had higher Td coverage, and persons who reported living in the Midwest or West had 
higher Tdap coverage while those who reported living in the Midwest had higher Td 
coverage (Table 2).
In the multivariable analysis, characteristics independently associated with an increased 
likelihood of Td vaccination among adults ≥18 years were: younger age; AIAN race; 
reporting never having been married; higher education; household income ≥$50,000; living 
in the West or Midwest regions of the United States; reporting excellent, very good, or good 
health; having health insurance; having a personal health care provider; having a routine 
checkup in the previous year; reporting receipt of influenza vaccination in the previous year; 
and having ever received pneumococcal vaccination (Table 3). Being female, African 
American, Hispanic, Asian, widowed, divorced, or separated were independently associated 
with a decreased likelihood of Td vaccination among adults. Characteristics independently 
associated with an increased likelihood of Tdap vaccination among adults ≥18 years were 
similar to those for Td, except female sex and not being in the work force were also 
independently associated with an increased likelihood of Tdap vaccination (Table 3).
Td coverage varied widely among the 50 states and D.C., ranging from 47.8% in Nevada to 
73.1% in Minnesota with a median of 58.7%. Coverage was below 50% in four states 
(Nevada, Mississippi, New Jersey, and Arkansas), and coverage was above 70% in three 
states (Wisconsin, Vermont, and Minnesota) (Table 4). Among adults ≥18 years, Tdap 
vaccination coverage ranged from 17.7% in Mississippi to 47.6% in Minnesota with a 
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median of 28.2%. Tdap vaccination coverage varied substantially by state. Coverage was 
below 20% in three states (Mississippi, Florida, New Jersey), and coverage was above 45% 
in three states (Wisconsin, Vermont, and Minnesota) (Table 4).
Depending on what proportion of excluded respondents actually received Tdap, the 
sensitivity analysis showed that actual Tdap coverage could fall within the range of 20.8% to 
48.9% for adults ≥18 years, 24.4% to 53.4% for adults 18–49 years, 18.3% to 46.3% for 
adults 50–64 years, and 13.8% to 39.8% for adults ≥65 years.
Discussion
By 2013, reported Td vaccination coverage was 57.5% among adults ≥18 years, similar to 
estimates in 1999 (60.4%) and 2008 (61.6%),11 indicating that approximately 40% adults 
had not received Td vaccination. In the United States, reported cases of tetanus have 
declined from 2044 cases in 1972 to 19 cases in 2009.12 Several factors have contributed to 
the decline in tetanus morbidity and mortality, including the widespread use of Td vaccine.13 
In addition to Td vaccine, other factors including improved wound care management, the use 
of tetanus immune globulin for post-exposure prophylaxis, and increased rural-to-urban 
migration with consequent decreased exposure to tetanus spores may also have contributed 
to the decline in tetanus morbidity and mortality.13 Although tetanus is rare in the United 
States, maintaining higher coverage of Td vaccination among the adult population is still 
important. Health-care providers should assess their patients’ Td vaccination status with 
particular emphasis on up-to-date vaccination, especially if patients are older adults, 
injection-drug users, persons with diabetes, or persons with wounds.13
Reported Tdap vaccination coverage in 2013 was low at 28.9%. Although coverage is low, 
Tdap vaccination coverage among adults has increased slowly over time.4, 11, 14–17 The 
number of adults affected by pertussis is more common compared with tetanus.1–3 The 
number of pertussis cases is likely underreported since pertussis can have nonspecific 
symptoms, especially among adults, and often goes undiagnosed.1–3 The results from our 
study indicated that over 70% of U.S. adults did not report having received a Tdap 
vaccination at the time of the 2013 BRFSS survey.
Because the Td and Tdap vaccination information was newly added to the 2013 BRFSS core 
questionnaire, this is the first study to assess state-specific Td and Tdap vaccination 
coverage among adult populations. Results from this study provide a baseline for state-level 
Td and Tdap coverage in the United States. Substantial differences in coverage among states 
were observed for both Td and Tdap vaccination. Variation in state coverage could be due to 
differing medical care delivery infrastructure, socioeconomic factors, state laws, 
effectiveness of state and local immunization programs, and other factors.18–22 Assessing 
local, state, and national adult vaccination programs is necessary for evaluating progress. For 
example, state level comparisons may aid in designing tailored intervention programs and 
sharing best practices.23
Both Td and Tdap vaccination coverage among adults 18–49 and 50–64 years were 
significantly higher than adults ≥65 years. This result remained unchanged after controlling 
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for other demographic and access-to-care variables. It is not unexpected that Tdap 
vaccination coverage among adults ≥65 years was lower compared with adults ≤64 years, 
because Tdap vaccination was initially recommended in 2006 only to adults ≤64 years. It 
was not until 2010, when ACIP first recommended limited use of Tdap in adults ≥65 years 
with close contact with an infant. In 2012, ACIP expanded the general adult Tdap 
recommendation to include all adults ≥65 years.4–6 Tdap vaccination coverage among adults 
≥65 years is likely to continue increasing as the recommendations for routine Tdap 
vaccination of adults ≥65 years is more widely implemented. Higher Tdap vaccination 
coverage among younger adults and females might indicate that young parents or pregnant 
women are more likely to receive vaccination since they are a source of pertussis 
transmission to infants.24, 25 One recent study indicated that Tdap vaccination coverage 
among pregnant women was higher (53.4% in 2011), and the higher Tdap vaccination 
coverage among pregnant women compared with general population may indicate that 
pregnant women were more likely to receive Tdap vaccination to protect themselves and 
their babies.25 Additionally, higher reported coverage in young adults might also reflect 
receipt of Tdap as older adolescents. For example, reported Tdap vaccination coverage 
among adolescents in 2013 (86%) was much higher compared with overall coverage among 
adults.26
The racial and ethnic disparities seen in this study are similar to those in other reports.
11, 14–17, 24
 Overall, coverage was lower among non-Hispanic blacks and Hispanics but was 
higher among AIAN compared with non-Hispanic whites. This finding persisted after taking 
into account demographic and access to care characteristics of respondents. Several factors 
may play a role in racial/ethnic differences in coverage including differences in attitudes 
toward vaccination and preventive care, the propensity to seek and accept vaccination, and 
differences in quality of care received by racial/ethnic populations.11, 14–17, 24, 27, 28
Higher education was independently associated with higher vaccination coverage. Higher 
education might be related to greater awareness of pertussis and its risk.3, 24 Additionally, 
having health insurance, having a personal health care provider, and having a routine 
checkup in the previous year were independently associated with higher vaccination 
coverage. These findings are consistent with previous reports.3, 11, 27, 29–33 Reported receipt 
of influenza and pneumococcal vaccination were also associated with vaccination and may 
reflect general health-seeking behavior and acceptance of or access to vaccinations, a 
positive attitude toward preventive measures, the quality of medical care or having providers 
who are more likely to vaccinate adults. Annual influenza vaccination could provide a 
platform for delivering Tdap vaccine and thus may help increase Tdap vaccination coverage 
among adult populations. Tdap vaccination coverage could be further improved if providers 
took advantage of other vaccination visits by adults to offer this vaccine.
The results from this study could be compared with estimates from the 2013 National Health 
Interview Survey (NHIS). The NHIS is a national household survey conducted annually by 
face-to-face interview and has higher response rates (61.2%) than BRFSS. Td coverage from 
the 2013 NHIS was somewhat higher than the estimates from BRFSS, and Tdap coverage 
was somewhat lower than BRFSS. Factors that may contribute to the differences in 
estimated coverage between the BRFSS and NHIS include a more representative sample 
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frame and higher response rates for the NHIS, survey mode (in person for the NHIS, 
telephone for BRFSS), and differences in survey operations and weighting procedures.
8–10, 17, 34
The findings in this report are subject to several limitations. First, vaccination coverage was 
self-reported and therefore might be subject to recall bias. Validity of Td and Tdap 
vaccination based on BRFSS were not reported; however, self-reporting of pneumococcal 
vaccination based on BRFSS was validated by medical record and had a sensitivity of 75% 
and a specificity of 83%.35 In addition, adult self-reported vaccination status has been shown 
to be sensitive, and sensitivities (if a person received vaccination, how often it will be shown 
positive in medical record) were 73.8% for pneumococcal, 92.1% for tetanus, 91.2% for 
human papillomavirus, 90.7% for shingles, 62.5% for hepatitis A, 72.6% for hepatitis B, and 
93.0% for influenza vaccinations.36 Self-reported vaccination has not been shown to be as 
specific, and specificities (if a person did not receive vaccination, how often it will be shown 
negative in medical record) were 90.7% for pneumococcal, 11.0% for tetanus, 76.1% for 
human papillomavirus, 89.7% for shingles, 84.0% for hepatitis A, 66.6% for hepatitis B, and 
65.7% for influenza vaccinations.36 Second, the response rates for the 2013 BRFSS were 
low at only 49.6% for land lines, 37.8% for cell phones, and 46.4% for the combined 
sample. Some selection bias may remain. However, the basic demographic characteristics by 
age, gender, and race/ethnicity from the 2013 BRFSS were similar to those observed in the 
2013 National Health Interview Survey (CDC unpublished data), which is considered a gold 
standard survey with a final response rate of 61.2% for the adult core data set.4 Third, many 
respondents were excluded from estimations of Tdap coverage, creating a potential for bias. 
Adults who reported a tetanus vaccination since 2005 but were unable to say whether Td or 
Tdap was given were excluded from the analysis. Sensitivity analyses were conducted to 
evaluate the magnitude of potential bias. Depending on what proportion of excluded 
respondents actually received Tdap, self-reported Tdap coverage among adult ≥18 years 
could range from 20.8% to 48.9%. Regardless, estimated Tdap vaccination coverage was 
low in 2013.
In summary, by 2013, our study indicated that more than 40% adults had not received Td 
and more than 70% adults had not received Tdap vaccinations. Most importantly, this is the 
first study to assess Td and Tdap vaccination at state level, and the results from this study 
provide a baseline for state level Td and Tdap coverage in the United States. The findings in 
this study showed that there was great variation in coverage by state; for example, only 
17.7% of adults in Mississippi reported receipt of Tdap, but Tdap coverage was as high as 
47.6% in Minnesota. Implementation of evidence-based programs are needed to improve Td 
and Tdap vaccination, and state immunization programs are encouraged to engage providers 
to implement interventions shown to be effective in increasing vaccination among adults.
23, 37–39
 Additionally, the Affordable Care Act (ACA) program should also help to improve 
Td and Tdap vaccination coverage among adult populations.40, 41
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Table 1
Sample characteristics among adults ≥18 years, BRFSS 2013
Characteristic
All adults
Sample (N) Weighted* %
Total 479,201 100.0
Age
 18–49 years 169,437 55.0
 50–64 years 151,258 26.3
 ≥65 years 158,506 18.7
Sex
 Male 196,743 48.7
 Female 282,458 51.3
Race/ethnicity
 White, non-Hispanic 373,391 65.0
 Black, non-Hispanic 38,675 11.7
 Hispanic 30,804 15.6
 Asian, non-Hispanic 8,826 4.6
 American Indian/Alaska Native, non-Hispanic 7,627 1.0
 Other 12,260 1.9
Marital status
 Married or unmarried couple 260,139 56.1
 Divorced, widowed, or separated 143,438 20.2
 Never married 73,004 23.7
Education level
 Less than high school 40,379 15.1
 High school graduate 139,754 28.6
 Some college or technical school 131,282 30.8
 College graduate or higher education 165,955 25.5
Employment
 Employed 236,666 56.1
 Unemployed 25,470 7.5
 Not in work force 214,068 36.4
Income
 <20,000 83,028 21.4
 20,000–49,999 149,216 34.8
 50,000–74,999 64,533 14.8
 75,000+ 114,896 29.0
Region
 Northeast 83,032 18.0
 Midwest 130,934 21.3
 South 158,223 37.3
 West 107,012 23.3
Am J Prev Med. Author manuscript; available in PMC 2018 February 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lu et al. Page 12
Characteristic
All adults
Sample (N) Weighted* %
Perceived health
 Excellent or very good 239,744 50.8
 Good 146,321 31.2
 Fair 63,876 13.2
 Poor 27,350 4.8
Have medical insurance
 Yes 423,296 82.5
 No 54,149 17.5
Have personal health care provider
 Yes 399,989 76.2
 No 77,534 23.8
Time since last routine checkup
 <1 year 346,683 69.6
 ≥1 year 122,100 30.4
Unable to see doctor due to cost
 Yes 58,441 15.9
 No 419,591 84.1
Influenza vaccination in the past 12 months
 Yes 204,945 38.8
 No 235,172 61.2
Ever received pneumococcal vaccination
 Yes 159,210 32.1
 No 238,056 67.9
*Census-based population was used to base the age/sex/race-ethnicity weights used in the analyses.
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Table 2
Td and Tdap vaccination coverage among adults by demographic and access-to-care variables, BRFSS 2013
Characteristic
Td vaccination coverage Tdap vaccination coverage
% (95% CI) % (95% CI)
Total 57.5 (57.2–57.9) 28.9 (28.5–29.2)
Age
 18–49 years 61.3 (60.9–61.8)* 34.4 (33.9–35.0)*
 50–64 years 56.0 (55.5–56.6)* 25.4 (24.8–26.0)*
 ≥65 yearsa 48.9 (48.3–49.5) 18.7 (18.2–19.2)
Sex
 Malea 59.5 (59.0–59.9) 27.4 (26.8–27.9)
 Female 55.7 (55.3–56.1)* 30.2 (29.7–30.7)*
Race/ethnicity
 White, non-Hispanica 59.3 (58.9–59.6) 29.9 (29.6–30.3)
 Black, non-Hispanic 53.4 (52.3–54.4)* 25.3 (24.2–26.4)*
 Hispanic 52.7 (51.6–53.9)* 26.0 (24.8–27.3)*
 Asian, non-Hispanic 52.6 (50.2–55.0)* 30.6 (28.1–33.3)
 American Indian/Alaska Native, non-Hispanic 64.1 (61.2–66.9)* 34.3 (31.3–37.4)*
 Other 60.5 (58.3–62.7) 30.2 (27.8–32.8)
Marital status
 Married or unmarried couplea 58.0 (57.6–58.4) 29.8 (29.4–30.3)
 Divorced, widowed, or separated 51.3 (50.6–51.9)* 21.4 (20.8–22.1)*
 Never married 62.0 (61.2–62.8)* 33.6 (32.7–34.5)*
Education level
 Less than high schoola 51.1 (50.0–52.2) 20.8 (19.7–21.9)
 High school graduate 54.5 (54.0–55.1)* 24.0 (23.4–24.6)*
 Some college or technical school 60.3 (59.7–60.9)* 31.3 (30.6–31.9)*
 College graduate or higher education 61.1 (60.6–61.6)* 35.8 (35.2–36.3)*
Employment
 Employeda 59.0 (58.6–59.4) 30.7 (30.3–31.2)
 Unemployed 56.1 (54.8–57.4)* 26.5 (25.2–27.9)*
 Not in work force 55.7 (55.1–56.2)* 26.6 (26.1–27.2)*
Income
 <20,000a 53.3 (52.4–54.1) 24.8 (23.9–25.6)
 20,000–49,999 55.2 (54.7–55.8)* 25.8 (25.2–26.4)
 50,000–74,999 60.2 (59.4–61.0)* 31.4 (30.5–32.3)*
 75,000+ 62.5 (61.9–63.1)* 35.8 (35.1–36.5)*
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Characteristic
Td vaccination coverage Tdap vaccination coverage
% (95% CI) % (95% CI)
Region
 Northeasta 57.5 (56.8–58.2) 27.3 (26.6–28.1)
 Midwest 60.4 (59.8–61.0)* 31.1 (30.5–31.8)*
 South 55.8 (55.3–56.4)* 25.4 (24.9–26.0)*
 West 57.6 (56.7–58.4) 33.0 (32.2–33.9)*
Perceived health
 Excellent or very good 60.2 (59.8–60.7)* 32.9 (32.4–33.4)*
 Good 55.6 (55.0–56.2)* 26.1 (25.4–26.7)*
 Fair 53.0 (52.0–53.9) 23.1 (22.1–24.1)*
 Poora 54.0 (52.6–55.4) 20.8 (19.4–22.2)
Have medical insurance
 Yes 59.2 (58.9–59.6)* 30.6 (30.2–31.0)*
 Noa 49.2 (48.3–50.1) 20.9 (20.0–21.7)
Have personal health care provider
 Yes 59.5 (59.2–59.9)* 30.7 (30.3–31.1)*
 Noa 51.0 (50.3–51.8) 23.3 (22.5–24.0)
Time since last routine checkup
 <1 year 60.7 (60.3–61.1)* 31.8 (31.4–32.2)*
 ≥1 yeara 51.5 (50.9–52.1) 23.5 (22.9–24.2)
Unable to see doctor due to cost
 Yesa 53.2 (52.3–54.1) 23.9 (23.0–24.7)
 No 58.4 (58.0–58.7)* 29.9 (29.5–30.3)*
Influenza vaccination in the past 12 months
 Yes 63.1 (62.6–63.5)* 37.1 (36.5–37.7)*
 Noa 54.1 (53.7–54.5) 23.8 (23.4–24.3)
Ever received pneumococcal vaccination
 Yes 63.2 (62.7–63.8)* 35.2 (34.5–35.9)*
 Noa 53.0 (52.6–53.4) 24.9 (24.5–25.4)
Note: Boldface indicates statistical significance (p<0.05).
*p < 0.05 by t-test comparing against reference group.
a
Reference level.
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Table 3
Multivariable logistic regression analysis of adults who reported received Td or Tdap vaccination, BRFSS 
2013
Characteristic
Adjusted prevalence ratio (PR)
Td vaccination Tdap vaccination
PR (95% CI) PR (95% CI)
Total
Age
 18–49 years 1.57 (1.54, 1.61)* 2.77 (2.63, 2.91)*
 50–64 years 1.37 (1.34, 1.41)* 1.90 (1.80, 2.00)*
 ≥65 years Reference Reference
Sex
 Male Reference Reference
 Female 0.92 (0.91, 0.93)* 1.06 (1.03, 1.09)*
Race/ethnicity
 White, non-Hispanic Reference Reference
 Black, non-Hispanic 0.90 (0.88, 0.93)* 0.91 (0.87, 0.96)*
 Hispanic 0.92 (0.89, 0.94)* 0.93 (0.88, 0.98)*
 Asian, non-Hispanic 0.84 (0.79, 0.89)* 0.86 (0.77, 0.95)*
 American Indian/Alaska Native, non-Hispanic 1.07 (1.02, 1.13)* 1.13 (1.03, 1.24)*
 Other 1.01 (0.97, 1.06) 0.98 (0.90, 1.08)
Marital status
 Married or unmarried couple Reference Reference
 Divorced, widowed, or separated 0.97 (0.96, 0.99)* 0.92 (0.89, 0.96)*
 Never married 1.04 (1.02, 1.06)* 1.09 (1.05, 1.14)*
Education level
 Less than high school Reference Reference
 High school graduate 0.98 (0.95, 1.01) 0.99 (0.93, 1.06)
 Some college or technical school 1.05 (1.02, 1.08)* 1.15 (1.08, 1.23)*
 College graduate or higher education 1.04 (1.01, 1.07)* 1.25 (1.17, 1.33)*
Employment
 Employed Reference Reference
 Unemployed 1.02 (0.99, 1.04) 1.01 (0.95, 1.08)
 Not in work force 1.01 (1.00, 1.03) 1.05 (1.01, 1.09)*
Income
 <20,000 Reference Reference
 20,000–49,999 1.00 (0.98, 1.02) 0.97 (0.92, 1.01)
 50,000–74,999 1.03 (1.01, 1.06)* 1.03 (0.98, 1.09)
 75,000+ 1.04 (1.01, 1.06)* 1.06 (1.01, 1.12)*
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Characteristic
Adjusted prevalence ratio (PR)
Td vaccination Tdap vaccination
PR (95% CI) PR (95% CI)
Region
 Northeast Reference Reference
 Midwest 1.06 (1.04, 1.08)* 1.15 (1.11, 1.20)*
 South 1.00 (0.98, 1.02) 0.99 (0.95, 1.02)
 West 1.06 (1.04, 1.08)* 1.27 (1.22, 1.32)*
Perceived health
 Excellent or very good 1.07 (1.04, 1.11)* 1.34 (1.24, 1.46)*
 Good 1.04 (1.00, 1.07)* 1.18 (1.09, 1.28)*
 Fair 1.01 (0.98, 1.05) 1.14 (1.04, 1.24)*
 Poor Reference Reference
Have medical insurance
 Yes 1.07 (1.04, 1.09)* 1.12 (1.06, 1.18)*
 No Reference Reference
Have personal health care provider
 Yes 1.11 (1.08, 1.13)* 1.13 (1.08, 1.18)*
 No Reference Reference
Time since last routine checkup
 <1 year 1.17 (1.15, 1.19)* 1.29 (1.25, 1.34)*
 ≥1 year Reference Reference
Unable to see doctor due to cost
 Yes Reference Reference
 No 0.98 (0.96, 1.00) 1.02 (0.98, 1.07)
Influenza vaccination in the past 12 months
 Yes 1.14 (1.12, 1.15)* 1.48 (1.44, 1.53)*
 No Reference Reference
Ever received pneumococcal vaccination
 Yes 1.26 (1.25, 1.28)* 1.60 (1.55, 1.65)*
 No Reference Reference
Note: Boldface indicates statistical significance (p<0.05).
*p < 0.05 comparing against the reference group.
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Table 4
State-specific Td and Tdap vaccination coverage adults ≥18 years, BRFSS 2013
Sample size Td vaccination coverage Tdap vaccination coverage
State % (95% CI) % (95% CI)
Total 479,201 57.5 (57.2–57.9) 28.9 (28.5–29.2)
Median 58.7 28.2
Alabama 6,452 53.5 (51.5–55.4) 24.2 (22.3–26.3)
Alaska 4,536 60.3 (58.0–62.5) 33.5 (31.0–36.1)
Arizona 4,207 53.1 (50.1–56.0) 24.0 (21.3–26.8)
Arkansas 5,209 49.5 (47.3–51.6) 20.8 (18.8–23.1)
California 11,508 56.0 (54.5–57.4) 32.3 (30.8–33.8)
Colorado 13,491 64.2 (63.0–65.4) 36.8 (35.4–38.3)
Connecticut 7,613 55.7 (53.8–57.5) 25.9 (23.9–27.9)
Delaware 5,152 58.7 (56.7–60.7) 27.0 (24.7–29.4)
District of Columbia 4,842 57.7 (55.1–60.2) 31.8 (29.0–34.7)
Florida 33,788 51.2 (49.9–52.5) 18.6 (17.4–19.9)
Georgia 8,051 55.0 (53.4–56.7) 25.2 (23.5–26.9)
Hawaii 7,788 55.5 (53.7–57.3) 20.7 (19.0–22.5)
Idaho 5,575 56.9 (54.8–58.9) 27.1 (25.0–29.4)
Illinois 5,586 54.8 (52.8–56.8) 27.9 (25.8–30.0)
Indiana 10,241 56.3 (54.9–57.6) 24.8 (23.3–26.4)
Iowa 8,095 65.5 (64.0–67.0) 35.5 (33.7–37.4)
Kansas 23,140 63.9 (63.1–64.7) 35.1 (34.1–36.1)
Kentucky 10,934 56.4 (54.8–57.9) 25.7 (24.1–27.4)
Louisiana 5,208 55.8 (53.4–58.1) 21.5 (19.1–24.0)
Maine 8,032 69.0 (67.6–70.5) 37.2 (35.3–39.1)
Maryland 12,838 59.0 (57.6–60.5) 27.0 (25.4–28.6)
Massachusetts 14,917 67.1 (65.7–68.4) 37.8 (36.1–39.6)
Michigan 12,647 60.0 (58.8–61.3) 27.6 (26.3–28.9)
Minnesota 14,182 73.1 (71.6–74.6) 47.6 (45.5–49.6)
Mississippi 7,401 48.3 (46.5–50.2) 17.7 (16.0–19.5)
Missouri 7,056 59.8 (58.0–61.7) 28.8 (26.7–31.0)
Montana 9,641 59.1 (57.6–60.5) 33.3 (31.7–35.0)
Nebraska 17,021 60.2 (58.9–61.5) 32.4 (30.9–34.0)
Nevada 5,047 47.8 (45.0–50.6) 21.6 (19.0–24.3)
New Hampshire 6,384 69.3 (67.6–71.0) 41.3 (39.1–43.6)
New Jersey 13,186 48.5 (47.0–50.0) 19.6 (18.3–20.9)
New Mexico 9,226 59.0 (57.4–60.6) 33.1 (31.3–34.9)
New York 8,812 55.1 (53.5–56.6) 24.6 (23.0–26.3)
North Carolina 8,769 64.1 (62.6–65.6) 36.0 (34.2–37.8)
North Dakota 7,731 68.6 (67.0–70.1) 40.3 (38.2–42.4)
Ohio 11,853 56.6 (55.1–58.0) 26.3 (24.9–27.9)
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Sample size Td vaccination coverage Tdap vaccination coverage
State % (95% CI) % (95% CI)
Oklahoma 8,202 57.2 (55.7–58.7) 29.1 (27.5–30.9)
Oregon 5,909 60.5 (58.6–62.4) 35.5 (33.4–37.7)
Pennsylvania 11,309 59.3 (57.9–60.6) 28.2 (26.7–29.7)
Rhode Island 6,455 61.8 (59.9–63.6) 35.4 (33.3–37.7)
South Carolina 10,603 58.1 (56.6–59.6) 24.6 (23.0–26.3)
South Dakota 6,860 64.8 (62.7–66.8) 36.2 (33.7–38.9)
Tennessee 5,755 52.8 (50.7–54.9) 26.7 (24.6–28.8)
Texas 10,788 56.6 (55.0–58.3) 26.3 (24.7–28.1)
Utah 12,649 59.9 (58.7–61.1) 36.9 (35.6–38.3)
Vermont 6,324 72.6 (71.1–74.2) 47.6 (45.5–49.7)
Virginia 8,377 59.7 (58.1–61.3) 31.5 (29.7–33.4)
Washington 11,065 65.6 (64.2–66.9) 47.0 (45.4–48.5)
West Virginia 5,854 55.1 (53.4–56.7) 22.1 (20.4–23.8)
Wisconsin 6,522 70.3 (68.3–72.2) 43.7 (41.3–46.1)
Wyoming 6,370 56.1 (54.2–58.0) 27.8 (25.8–29.9)
range 47.8–73.1 17.7–47.6
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